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Addressing Therapeutic Options for Ebola Virus Infection in Current
and Future Outbreaks
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Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USAa; University of Lille, Faculty of Medicine, CHRU
Lille, Laboratory of Virology, Lille, Franceb; Centre d’Etudes Paleopathologiques du Nord, Walincourt-Selvigny, Francec
Ebola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has
been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen
in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for
development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options
for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results from in vitro models.
We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based
drugs, which are under development and being tested in animal models or in vitro using various cell types. Our paper discusses
strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those
that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We un-
derline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.
Since the first recognized outbreak in 1976, Ebola virus hassurfaced two dozen times, but until 2014 it had sickened fewer
than 2,500 people altogether (1, 2). The current outbreak of Ebola
virus in West Africa is unprecedented, causing more cases and
fatalities than all previous outbreaks combined. As of 10 July 2015,
the outbreak includes 27,621 reported cases with 11,268 deaths
(1). The ongoing epidemic in West Africa is centered in Guinea,
Sierra Leone, and Liberia, but Ebola virus can pose a threat to
uninfected populations in other parts of the world, including the
United States and Europe, by accidental importation by infected
individuals from regions where it is endemic. While the number of
cases has decreased during recent months, with new cases still
emerging each week the virus is far from eradicated. Furthermore,
Ebola virus may resurface, as has happened several times during
the last 40 years (3).
Most human infections with Ebola virus occur in remote areas
that lack modern scientific equipment, making field research dif-
ficult. Traditional containment efforts have stopped every out-
break to date within a few months, which has left few opportuni-
ties for the researchers to test novel treatments. Due to extreme
risk, research is limited to biosafety level 4 (BSL-4) containment
facilities, which are not available in many research centers. Re-
search directed at finding efficacious anti-Ebola virus therapies
and vaccines by various organizations has so far been slow due to
the lack of sufficient resources. Only recently have more concerted
efforts been made and resources employed in developing effica-
cious anti-Ebola virus treatments (4, 5). These recent approaches
have resulted in the development of several drugs, some of which
have been examined in early clinical trials in humans. This review
summarizes and evaluates the potential of current experimental
candidates for treating Ebola virus disease (EVD) with regard to
their feasibility and use in the clinic.
While no approved drug has been shown to cure EVD, we have
examined the scientific rationale and relevance of using existing
therapies with safety records to treat Ebola patients. They can play
an important role in reducing or preventing Ebola virus pathoge-
nicity, thereby saving the lives of Ebola virus-infected individuals
(6, 7). Further, combination therapy may offer better efficacy in
treating Ebola patients. The scope of the present paper is to un-
derline the strategies that will permit us to not only face the cur-
rent epidemic but also to become better prepared for confronting
future outbreaks of Ebola.
EBOLA VIRUS DISEASE
It is important to understand the molecular properties of Ebola
virus and host responses implicated in pathogenesis, because they
can be exploited to develop effective drugs, including immuno-
therapeutics, against the virus.
The family Filoviridae includes the Ebola viruses and the Mar-
burg viruses (8). The Ebola filovirus is subdivided into 5 different
species: the Zaire (ZEBOV), Sudan (SUDV), Taï Forest (TAFV),
Bundibugyo (BDBV), and Reston agents (RESTV), which differ in
sequence and the number and location of gene overlaps and with
respect to virulence (9). Ebola virus is a nonsegmented, negative-
sense, single-stranded RNA virus. Ebola viruses have been associ-
ated with repeated outbreaks of severe hemorrhagic fever with
high fatality rates (10). Fatal outcomes in Ebola patients were
shown to correlate with the viral load in the blood (11).
The trimeric envelope glycoprotein (GP) spikes of the filovi-
ruses are believed to mediate their entry into host cells via endo-
cytic pathways. Within endo/lysosomal compartments, host en-
dosomal cysteine proteases (cathepsins) cleave the filoviral GP1
protein to generate an entry intermediate comprising an N-termi-
nal GP1 fragment and GP2 (12–14). Underlying the viral mem-
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brane is a viral matrix comprised mainly of viral protein 40
(VP40). Within the particle is the uncapped, single-stranded RNA
genome, which is coated by the viral nucleoprotein (NP). Also
associated with the encapsidated genomic RNA are the virus-en-
coded proteins VP35, VP30, VP24, and the large protein (L). The
L protein provides the RNA-dependent RNA polymerase activity
of the complex. Targeting these viral proteins may be an effective
strategy to treat the disease (15–17).
Ebola virus enters the human body via mucosal surfaces, abra-
sions and injuries to the skin, or by direct parental transmission
(18). The virus has been successfully isolated from skin (biopsy
specimens) and body fluids (19, 20). The route of transmission
seems to affect the disease outcome; in a nonhuman primate
(NHP) model, faster disease progression was reported in animals
infected via injection than those that received an aerosol challenge
(21).
Postmortem studies of patients and experimentally infected
animals have demonstrated that infection of immune cells (mac-
rophages, monocytes, and dendritic cells), epithelial and endothe-
lial cells, fibroblasts, hepatocytes, and adrenal gland tissue (22,
23). It is believed that Ebola viruses exhibit a preference for mono-
nuclear cells in the early stage of infection for rapid virus replica-
tion (24, 25). Replication in infected cells is very efficient, resulting
in a rapid and high peak viremia (22). The extreme level of repli-
cation reflects the ability of Ebola virus to very effectively coun-
teract host antiviral defenses, particularly interferon (IFN) re-
sponses, which typically serve as critical innate immune responses
toward virus infection (26). Furthermore, viral proteins VP24 and
VP35 are involved (although not fully understood) in the
inhibition of the host type 1 interferon response (27, 28). Ebola
virus also infects dendritic cells, knocking down their function
and evading innate immunity, resulting in immunodepression
(29, 30).
Cytokines released from infected cells recruit more mononu-
clear cells to the initial infection site, in turn amplifying infection
and apoptosis of mononuclear cells (31, 32). At the same time,
virions are systemically spread through the blood circulation. Al-
though Ebola virus cannot infect lymphocytes productively, stud-
ies in monkey models have shown that Ebola virus infection can
cause apoptosis in bystander CD4 and CD8 lymphocytes and in
NK cells (33). There is also multifocal necrosis, most predomi-
nantly in the liver, spleen, kidneys, testes, and ovaries (29, 34). The
marked increase in proinflammatory cytokines seen in experi-
mentally infected animals and in plasma samples from patients
with Ebola virus infection can contribute to enhanced vasodila-
tion and a resulting “cytokine storm” condition (29, 35). The
combined effect of the immune evasion strategies along with elic-
iting acute immune activation, inflammation, and the “cytokine
storm” is lethal for the host. The detrimental effects to hosts with
other RNA virus infections by the immune activation and cyto-
kine storm were previously described (36). During the middle or
advanced stage of EVD, inflammatory molecule-caused vasodila-
tation results in both internal and external bleeding. Since hepa-
tocyte infection leads to liver damage, the coagulation system be-
comes disordered (23, 37). These devastating effects result in the
clinical symptoms of hemorrhagic lesions in the skin, mucous
membranes, and visceral organs and large effusions in body cavi-
ties. An overexpression of tissue factor in monocytes/macro-
phages can occur and results in overactivation of the extrinsic
pathway of coagulation, followed by a consumptive coagulopathy
and eventually a disseminated intravascular coagulation. If viral
spread cannot be controlled, patients can succumb to organ fail-
ure or secondary bacterial infection (25, 38).
Frequent mutations in the genome of Ebola virus and emer-
gence of new strains have recently been reported (39, 40, 41). This
has led to new challenges for researchers to discover novel thera-
peutic interventions that can work against the new strains of Ebola
virus (42, 43). Mutations in RNA viruses, in which the poly-
merases are error prone, is a well-described phenomenon. Re-
cently, after sequencing at a depth of 2,000 on average, more
than 300 genetic changes have been found in the 2014 Ebola virus
genomes (39). This high-resolution approach allowed the detec-
tion of multiple mutations that alter protein sequences, which
could be potential targets for future therapies.
POTENTIAL CANDIDATES FOR EBOLA VIRUS TREATMENT
Among the Ebola virus treatment candidates, the frontrunners for
human trials are (i) favipiravir (T-705), an antiviral compound
currently licensed for influenza outbreaks, (ii) convalescent
plasma, removed from surviving/cured Ebola patients and which
contains anti-Ebola virus antibodies (while efforts to start a blood
plasma trial continued, a clinical trial with simpler whole blood
from surviving individuals was stopped), (iii) ZMapp, a cocktail of
three monoclonal antibodies (MAbs) targeting both distinct and
overlapping parts of the Ebola virus GP that it uses to infect hu-
mans, (iv) brincidofovir, an experimental drug developed for the
treatment of cytomegalovirus and adenovirus infections which
has been shown to stop Ebola virus replication in test tubes (the
clinical trial with this drug was recently halted) (Table 1).
Favipiravir (T-705) was first described by Toyama Chemicals
as a selective inhibitor of influenza virus replication with minimal
cytotoxicity (44, 45). It was shown to inhibit the viral RNA-depen-
dent RNA polymerase via an active metabolite and to induce a
high rate of lethal RNA mutations (44, 46). Recently, it was shown
that T-705 was effective at inhibiting Ebola virus replication in
vitro without any observed cytotoxicity under the experimental
conditions used (47, 48). When dosed orally twice daily to type I
IFN-/ receptor knockout mice, T-705 was able to prevent mor-
tality in 100% of the animals. Favipiravir prevented death in mice
infected with Ebola virus even when treatment was started 6 days
postinfection (47). The advantage of using favipiravir in an Ebola
outbreak is that it has already been extensively tested for use as an
antiviral in human trials for influenza in Japan, can be used orally,
and is available immediately.
Preliminary data from the clinical trial with favipiravir under-
taken at Médecins Sans Frontières (MSF) centers indicate the ab-
sence of efficacy when given to individuals with a very high level of
viral replication and who have already developed serious visceral
involvement. Encouraging signs of efficacy, however, have been
reported in patients with a moderate level of viremia and who have
not yet developed severe visceral lesions (reported in a conference
on Retroviruses and Opportunistic Infections, Seattle, WA, 25
February 2015). Clearly, the results of this noncomparative trial
have to be confirmed in a larger number of Ebola patients.
Postexposure treatment with antibody from NHPs that sur-
vived challenge with filoviruses under controlled conditions re-
sulted in protection of NHPs from Ebola virus disease (49). In
EVD patients, survivors develop neutralizing antibodies against
the virus, whereas patients who succumb to the infection lack a
neutralizing humoral response (50). In theory, immunization
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with plasma from cured/surviving Ebola patients should help a
patient fight the virus. One published report showed that seven
out of eight people who received whole blood from survivors dur-
ing a 1995 Ebola outbreak in the Democratic Republic of the
Congo survived (51), but they were treated late in the course of
disease and some researchers believe that they would probably
have recovered without the serum. Due to the potential for anti-
bodies to enhance viral infections via antibody enhancement
mechanisms (52), a note of caution is in order for the use of pas-
sive immunization. Antibody-dependent enhancement seems to
increase infectivity of the virus in vitro not only for Ebola virus but
also the closely related Marburg virus (53). It is to be emphasized
that these so-called “convalescent-phase sera” were actually “con-
valescent plasma,” since an anticoagulant would have to be used in
collection of the donated blood. The blood donors and recipients
must have the same or matched blood group, and the donor-
recipient compatibility for blood plasma is the converse of that of
red blood cells. For example, the ABO blood group antibodies in
donated plasma are able to bind with the recipient’s red blood
cells, thus causing agglutination reactions. Also, this convalescent
plasma is not a perfectly manufactured drug. The effectiveness of
the serum could vary from survivor to survivor. No published data
are yet available to conclude whether the convalescent therapy
trial recently initiated has resulted in the expected treatment effi-
cacy.
Antibody-based EVD therapies have been studied by using not
only convalescent-phase serum but also with a cocktail of MAbs.
The monoclonal antibody-based drug against Ebola virus that has
attracted attention is ZMapp, developed by Mapp Biopharmaceu-
tical Inc. ZMapp is a combination of available monoclonal anti-
bodies, i.e., c13C6 from MB-003 and two humanized monoclonal
antibodies from ZMab, c2G4 and C4G7. All three MAbs recognize
conformational epitopes located on GP2 or the stem region of the
GP trimer, while the remaining three antibodies from MB-003
and ZMAb bind to the trimer head (54). When these antibodies
were given to experimental animals 24 or 48 h after infection, four
of six macaques survived with little viremia and only a few clinical
symptoms (55, 56). Three doses of ZMapp were given to challenge
rhesus macaques at 5, 8, and 11 days (50 mg/kg of body weight per
dose), and 100% of them survived. Animals showed EVD symp-
toms and detectable viremia at 5 days postinfection (p.i.) before
treatment with ZMapp, but viral loads could not be detected in
blood 21 days p.i. (57). This study is significant in that people may
be rescued by an antibody-based therapeutic agent, even when
EVD symptoms have appeared.
ZMapp, the experimental drug for EVD, gained considerable
attention when it was given to a few infected aid workers at the
height of the recent epidemic. Of the few doses then available,
some of the Ebola patients infused with ZMapp serum survived.
However, it could not be determined if the drug actually benefited
those patients, because it was not administered within the context
of a clinical trial; also, it was often administered in combination
with other experimental therapies. Based on these few sporadic
TABLE 1 Anti-Ebola virus therapeutic candidates undergoing trials in areas of endemicity in West Africa
Drug name Target Test results in vitro and/or in animals Route of administration Observations
Favipiravir (T-705) Inhibition of viral RNA
polymerase
Prevents virus replication in vitro;
protective in mouse model
Can be given orally, available
immediately; active
against influenza virus
Stable at room temp; undergoing
trial in Guinea in
collaboration with MSF; no
published data from trial
available yet




Polyclonal antibodies from NHPs
survived EVD under controlled
conditions, induced protection in
monkeys when given multiple
doses in clinical phase
Not a perfectly
manufactured drug; given





efficacy testing in human trial
in Guinea by Tropical
Medicine Institute, Antwerp;
no scientific data for efficacy
available
ZMapp Cocktail of monoclonal
antibody-based drugs
targeting both distinct and
overlapping parts of the
Ebola virus GP
Treatment resulted in 100% survival
in NHPs challenged with Kiwit
strain, inhibited epidemic strain
replication in cell culture
Given by injection; limited
supply; production of
sufficient doses is needed
for immediate treatment
in an epidemic situation
Shipping and storage temp is
20°C, manufacturer is
currently gathering stability
data at 4°C; sporadically used
in humans; trial in Liberia
started in participation of
NIAID and Liberian
government at end of
February 2015; no safety or
efficacy data presently
available




Inhibits virus in vitro; ongoing
studies in guinea pigs and mice
Tested only in in vitro assays;
testing in monkeys is
uncertain because an
enzyme in animals rapidly
inactivates the drug
Stable at room temp and does
not require cold storage; trial
started in Sierra Leone by the
University of Oxford (trial has
now been stopped, reason
given was insufficient no. of
patients)
a The trial with brincidofovir, a potential broad-spectrum antiviral, was recently halted by Chimerix Inc., the manufacturer. The chemical structures of favipiravir and brincidofovir
have been illustrated previously (104).
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cases and the heterogeneity in outcomes, the efficacy of this drug
in patients cannot be accurately judged at this time.
The antibodies contained in ZMapp are now produced via the
tobacco plant Nicotiana benthamiana, i.e., in a bioproduction
process known as “pharming.” However, this technology may be
insufficiently robust to scale up the production of ZMapp for
combating the current Ebola outbreak in West Africa. A signifi-
cant progress in scaling up of production of ZMapp will be possi-
ble once the antibodies can be produced in genetically engineered
animal cells (e.g., Chinese hamster ovary cells), the biotechnology
industry’s usual production method.
Another drug that has attracted attention as a candidate for
EVD treatment is brincidofovir, which was designed to interfere
with viral DNA replication (58). Recently, Chimerix, the manu-
facturer, had two outside labs test the drug against Ebola virus;
they found that the drug did indeed inhibit the virus in test tube
studies (59). Unfortunately, brincidofovir cannot be tested in
monkeys, because an enzyme in the animals rapidly inactivates the
drug (5). Chimerix Inc. has recently scrapped testing of its exper-
imental antiviral agent in Ebola patients in Liberia, a trial that
began in January 2015. The reason given by the company is that
only a few patients were available for enrollment in the human
trial study in Liberia. Table 1 summarizes the target(s), route of
administration, and treatment outcome in animals or humans of
these candidate drugs undergoing initial trials.
SMALL-MOLECULE INHIBITORS OF EBOLA VIRUS INFECTION
Various antiviral studies on Ebola virus have identified via biolog-
ical screening and medicinal chemistry programs small-molecule
inhibitors of Ebola virus infection (60) (Table 2). TKM-Ebola is an
RNA inhibitor of the virus packaged in a lipid nanoparticle. It is a
cocktail of three small interfering RNAs (siRNAs) that target poly-
merase L, the membrane-associated protein VP24, and the poly-
merase complex protein VP35 genes of Zaire Ebola virus, formu-
TABLE 2 Small-molecule-based compounds that are under development for treating Ebola patientsa
Drug name Target
Testing in vitro and/
or animals Route of administration Observations
Chemical structure
reference(s)
TKM-Ebola RNAi-based drug inhibits
viral RNA; interferes
with proteins L, VP24,
and VP35
When given to monkeys, TKM-
Ebola provided 100% survival




storm” of Ebola virus








Suppresses disease in mice and
NHPs
Intravenous Stable at room temp for
mos.; gene-silencing drugs





BCX4430 Inhibits RNA polymerase
activity; a nonobligate
RNA chain terminator
Inhibits infection in vitro;
induces 90–100% survival in
mice after treatment
Intramuscular (150 mg/
kg twice daily) or oral
(twice daily) to mice
then inoculated with
lethal doses of Ebola
virus
Stable at laboratory temp;
has not yet been tested in
humans; no published








endosomes, a trait of
NPC1
Inhibits in vitro virus entry in
NPC1-dependent manner
Tested only in an in vitro
assay
Can be stored at room temp;
oral availability makes this
drug a good candidate for
treating Ebola patients in









Inhibits Ebola virus entry in vitro
in Vero E6 and HepG2 cell
lines; mediated 90%
protection in C57BL/6 mice
Intraperitoneal, C57BL/6
mice
Can be kept at room temp;
oral availability and
history of human use
make these drugs
promising candidates for
treating patients in remote
geographical locations
109, 110
FGI-103 Mechanism of action not
known
Treatment completely protects
mice; associated with delayed
cytokine response
Given in mice by
intraperitoneal
injection
Drug is probably stable at
room temp; no published
data available on storage
requirements; a potential
treatment for the
filoviruses Ebola virus and
Marburg virus; it has not
yet been tested in NHPs
or humans
111
a The advantages of these anti-Ebola virus compounds are that they do not need refrigeration and many of them can be given orally.
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lated with Tekmira’s lipid nanoparticle technology. Tekmira
recently has developed a modified RNA interference therapeutic
that specifically targets Ebola virus Guinea strain, which is cur-
rently circulating in Guinea. The Ebola virus Guinea strain is also
known as Ebola virus Makona, as it diverges slightly from the
Kikwit strain, which was the original target of TKM-Ebola. TKM-
Ebola has worked successfully in monkeys, the best animal model
(61). However, there is no experience in the field with this drug, or
at least none has been reported. Treatment with TKM-Ebola was
transiently placed on clinical hold to further investigate an en-
hanced cytokine-mediated inflammatory response in a recipient
who received a high dose of TKM-Ebola. Clinicians at that time
decided to skip treatment with TKM-Ebola, despite its promise,
because of worries that it could trigger overproduction of cyto-
kines, a dangerous inflammatory response also caused by Ebola
virus, and because of scant data from human trials.
The emergence of a new strain of virus poses a challenge for
researchers to discover novel therapeutic interventions adapted to
an emerging strain of Ebola virus. It has been shown in a seminal
study that lipid nanoparticle-encapsulated short siRNAs can be
adapted to target the new Makona outbreak strain of Ebola virus
and are able to mediate 100% protection of rhesus monkeys
against lethal challenge when treatment starts at day 3 postexpo-
sure (43). It has not yet been shown whether such a therapeutic
approach will provide in vivo efficacy in highly lethal human EVD.
Another drug, known as AVI-7537, is an experimental antiviral
agent that has been shown to offer efficacy against Ebola virus
infection in mice and monkeys (62, 63). This drug exerts its action
via gene silencing, and some safety and pharmacokinetic data in
humans are available for AVI-7537 (64). The gene-silencing drugs
are relatively difficult to make, and scaling up their production to
meet the demands for a public health emergency remains a chal-
lenging task.
BCX4430, a novel synthetic adenosine analogue, inhibits infec-
tion of distinct filoviruses in human cells (65). Biochemical,
reporter-based, and primer-extension assays indicate that
BCX4430, a nucleoside RNA polymerase inhibitor, is metabolized
to the active triphosphate (nucleotide) form by cellular kinases.
The drug nucleotide is recognized as a substrate by a viral enzyme
and then becomes incorporated into the newly synthesized viral
genome, leading to premature chain termination (65). It does not
incorporate into human RNA or DNA. BCX4430 is active in vitro
against Ebola virus and does not display any significant mutagen-
icity, as determined in an Ames assay. Intramuscular or oral,
twice-daily administration of BCX4430 to Ebola virus-infected
C57BL/6 mice, 4 h before infection, resulted in 100% and 90%
survival, respectively (65).
By using a haploid genetic screen, Carette et al. identified the
endo/lysosomal cholesterol transporter protein Niemann-Pick C1
(NPC1) as a key host element required for Ebola virus cellular
entry (66). Treatment with U18666A (67), which is known to
induce an NPC1 phenotype, or with imipramine (68), which me-
diates sphingomyelinase (ASMase) inhibition (69), reduced Ebola
virus infectivity in vitro.
The selective estrogen receptor (ER) modulators clomiphene
and toremiphene showed effective in vitro inhibition of Ebola vi-
rus infection in a screen of U.S. Food and Drug Administration
(FDA)-approved drugs (70). The observed in vitro antiviral effects
of clomiphene and toremiphene were independent of ER expres-
sion but were affected by NPC1 overexpression (71). Similar to
U18666A, these compounds induced cholesterol accumulation in
endosomes, a typical trait of the NPC1 phenotype, and Ebola virus
entry inhibition was accompanied by NPC1 overexpression. Dos-
ing of clomiphene and toremiphene to Ebola virus-challenged
C57BL/6 mice 1 hour postinfection (p.i.; 60 mg/kg) resulted in
survival rates of 90% and 50%, respectively, at day 28 p.i.
A green fluorescent protein (GFP)-Ebola virus-based high-
throughput screening assay identified FGI-103 as an effective
Ebola virus replication inhibitor (90% effective concentration,
330 nM) with no apparent in vitro cytotoxicity over the com-
pound concentration range tested (72). Prophylactic administra-
tion (1 h before Ebola virus infection) of FGI-103 to C57BL/6 mice
resulted in 100% protection. The mechanism of action of FGI-103
has, however, not yet been established.
Studies with the multiple-ion channel blockers amiodarone,
dronedarone, and the L-type calcium channel blocker verapamil
have shown these agents inhibit Ebola virus GP1,2-mediated cell
entry in EAhy cells (73). Recently, amiodarone and its main me-
tabolite, monodesethyl amiodarone (MDEA), has been shown to
inhibit Sudan Ebola virus infection in vitro (74). The drug acts by
interfering with the fusion of the viral envelope with the endo-
somal membrane (74). However, unapproved use of amiodarone
in human Ebola patients at one clinic in Sierra Leone was de-
scribed as “reckless” and may have actually contributed to an in-
creased likelihood of death (75). Therefore, it is vital to test the
safety and efficacy of any experimental drug in preclinical studies
in animal models prior to its use in humans. This is critically
important in the case of any drug targeting the host factors. Table
2 summarizes the potential anti-Ebola virus activities of small-
molecule-based compounds.
REPURPOSING EXISTING DRUGS FOR TREATMENT OF
EBOLA PATIENTS
The mechanisms of Ebola virus pathogenesis are only partially
understood, but the dysregulation of normal host immune re-
sponses (including destruction of monocytes/lymphocytes, im-
mune activation, and increased cytokine production, resulting in
a cytokine storm-like condition and development of coagulation
abnormalities) plays a crucial role in disease outcome (32, 76).
Recently, the role of enhanced inflammation in the progression of
Ebola virus disease was demonstrated (58). Four Ebola patients
who received care at Emory University Hospital presented striking
activation of both B and T cells that was manifested by expression
of activation phenotypic markers and production of inflamma-
tory cytokines (77). This is a significant observation that is made
in humans naturally infected with Ebola virus but not in animals
experimentally infected. As Ebola virus infection is accompanied
by an excessive inflammatory response, therapies that can limit
inflammatory responses are likely to bring clinical benefits to
Ebola patients (Fig. 1). In the absence of any effective anti-Ebola
virus drug or vaccine tested in human trials or approved by the
FDA, such an alternative therapeutic approach is of particular
interest. Accumulating evidence suggests that much of the ob-
served pathology of EVD is not the direct result of virus-induced
structural damage but rather is due to the release of soluble im-
mune mediators from Ebola virus-infected cells.
(i) Chloroquine. Several research groups have been searching
for FDA-approved drugs that have activity against Ebola virus.
Chloroquine emerged as one of the best in vitro Ebola virus inhib-
itors following a drug-repurposing screening (78). Both chloro-
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quine and the related compound hydroxychloroquine are also
used in the treatment of systemic lupus erythematous and rheu-
matoid arthritis for their anti-inflammatory properties (79).
These antimalarial agents accumulate in the endosomes and pre-
vent their acidification maturation, which are crucial steps in the
activation of not only lysosomal enzymes but also innate immune
receptors Toll-like receptor 7 (TLR7) and TLR9. It was shown that
Ebola and Marburg viruses pass through the endosomes and their
acidification is essential for exiting the endosomes, and that chlo-
roquine and hydroxychloroquine trap the viral particles, prevent-
ing their escape. Results of in vivo studies revealed that chloro-
quine was able to reduce mortality significantly (90% survival rate
at day 13 p.i.) when dosed at 90 mg/kg 4 h before infection (78).
Among monkeys treated with chloroquine, 80 to 90% survived
challenge with Ebola and Marburg viruses. Intraperitoneal ad-
ministration improved the survival to 100%. Since these drugs
target host proteins, the virus is unlikely to develop drug resis-
tance. Ebola virus-affected areas in West Africa are also areas
where malaria is endemic; hence, therapeutic use of chloroquine
has an added advantage because of its antimalarial activity.
(ii) Statins. Statins are lipid-lowering drugs that exhibit anti-
inflammatory and immune-modulatory properties, and lead to a
reduction of serum levels of CRP in the general population (80).
Statins have shown antiviral activity against influenza virus due to
their anti-inflammatory activities (81). All three statins, namely,
rosuvastatin, atorvastatin, and pravastatin, could lead to a signif-
icant reduction in serum levels of hsCRP and tumor necrosis fac-
tor alpha (TNF-) in HIV patients (82). Treatment with rosuvas-
tatin caused significantly greater decreases in total cholesterol and
low-density lipoprotein cholesterol than subjects on atorvastatin
or pravastatin. Cholesterol transport is important for the efficient
biosynthesis of Ebola virus. Whether reduction of cholesterol by
rosuvastatin can affect the biosynthesis machinery in Ebola virus
has not yet been clearly determined.
(iii) MAPK inhibitors. An siRNA screening for kinome gene
products revealed mitogen-activated protein kinase (MAPK),
phosphoinositide 3-kinases (PI3Ks), and calcium/calmodulin ki-
nases (CAMK2) as cell proteins that are significantly related to
Ebola virus infectivity (83). Accordingly, the PI3K inhibitor
LY294002 and CAMK2 inhibitor KN-93 effectively reduced Ebola
virus infection in Vero E6 cells when tested at 50 mM. The enzyme
p38 MAP kinase plays a central role in the signal transduction
cascade that leads to the production of both proinflammatory
cytokines TNF- and interleukin-1 (IL-1) (84, 85). Ebola virus
disease is associated with an excessive inflammatory cytokine re-
sponse; therefore, therapies that can control this host response
may prove clinically beneficial. Recently, p38 MAPK inhibitors,
particularly the standard compound SB202190, have been shown
to inhibit Ebola virus-mediated cytokine production from human
monocyte-derived dendritic cells in vitro (86). A series of pyridinyl
imidazole inhibitors of p38 MAPK (e.g., SB202190 and p38inK
III) inhibited viral entry into dendritic cells (86). In line with the
proinflammatory function of MAPK, dosing of the MAPK inhib-
itors resulted in much-reduced cytokine and chemokine release
levels upon Ebola virus infection, an important feature to mini-
mize Ebola virus virulence. Inhibitors are considered suitable tar-
gets in the treatment of inflammatory diseases such as rheumatoid
arthritis and inflammatory bowel disease. Pyridinyl imidazole or
other inhibitors of p38 MAP kinase may serve as antidisease agents
for Ebola virus infection.
FIG 1 Therapeutic agents that target Ebola virus pathogenicity. Chloroquine affects innate immune receptor activation and prevents viral escape from
endosomes. Statins, p38 MAPK inhibitors, artemisinins, and the sphingosine analogue FTY720 can limit a host’s excessive inflammatory response. Recombinant
nematode protein c2 is likely to control patients’ bleeding.
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(iv) Artemisinin. Artemisinin, an antimalarial drug used to
treat millions of malarial patients, has an established safety record
(87). Recent studies demonstrated the anti-inflammatory activi-
ties of artemisinins, which are attributed to the inhibition of Toll-
like receptors, Syk tyrosine kinase, and phospholipase C, PI3K/
Akt, MAPK, STAT-1/3/5, NF-B, Sp1, and Nrf2/ARE signaling
pathways (88). This anti-inflammatory property has made arte-
misinin a potential antidisease therapeutic for Ebola patients in
addition to its antimalarial activity. There is also a possibility of
synthesizing novel artemisinin analogues with better clinical
pharmacology. Since West African countries have a high inci-
dence of malaria, use of a dual-targeted/bifunctional drug target-
ing both Ebola and malaria would be of great public health benefit.
(v) FTY720. FTY720 (an FDA-approved drug for multiple
sclerosis) is an oral S1P (sphingosine-1-phosphate) receptor mod-
ulator that has been shown to be a useful agent for prevention of
transplant rejection and autoimmune diseases (89, 90). A height-
ened immune activation manifested by a cytokine storm and sep-
sis inflammation is seen in Ebola patients. Treatment with an im-
munomodulatory therapeutic agent that will promote expansion
of regulatory T and/or B cells secreting anti-inflammatory cyto-
kines (IL-10, transforming growth factor ) can dampen the im-
munopathologic response in Ebola patients. Recently, therapy
with AAL-R, a chiral sphingosine analogue of the clinical drug
FTY720, was shown to limit inflammation and mortality in mice
infected with highly pathogenic H1N1 influenza virus (91). Inter-
estingly, this treatment did not alter the generation of influenza
virus-neutralizing antibodies, and when given in combination
with oseltamivir, an anti-influenza virus drug, it resulted into a
significantly greater protection.
(vi) Anticoagulant therapy. A 38-year-old male doctor who
had contracted Ebola virus infection in Sierra Leone was airlifted
to University Hospital Frankfurt, Germany, on day 5 after disease
onset. The patient received a 3-day treatment course with FX06
(MChE-F4Pharma, Vienna, Austria), a fibrin-derived peptide un-
der clinical development for vascular leak syndrome. After FX06
administration, vascular leak syndrome and respiratory parame-
ters substantially improved (92). Infection with the Ebola virus
induces overexpression of the procoagulant tissue factor in pri-
mate monocytes and macrophages. The endothelium also con-
tributes to the coagulation disorders that characterize Ebola hem-
orrhagic fever. Recombinant nematode anticoagulant protein c2
(rNAPc2), an inhibitor of tissue factor when given to macaques,
increases the survival rate in Ebola virus-infected primates (93).
Postexposure protection with rNAPc2 against Ebola virus in pri-
mates provided a new foundation for therapeutic regimens that
target the disease process rather than destruction of the virus
(Fig. 1).
VALUE OF COMBINATIONAL TREATMENTS
Several Ebola patients who received experimental interventions in
the United States and Europe survived viral infection. A patient at
the Nebraska Medical Center, Omaha, NB, was given a combined
therapeutic that included convalescent-phase serum and brin-
cidofovir, and the patient was cured from Ebola virus infection
(94). The same is true for about 19 other Ebola patients who re-
ceived multiple experimental drugs, including ZMapp and favipi-
ravir. The question remains whether the successful outcome of the
treatment depended on the combinational therapeutics and/or
better supportive care in modern, well-staffed hospitals in the
Western world. At the very least, we can conclude that the combi-
national treatments did not harm anyone and are likely to be ben-
eficial.
A replication-defective recombinant human adenovirus sero-
type 5 (AdHu5) expressing consensus human alpha interferon
(Ad-IFN) has been developed as a broad-spectrum antiviral agent
(95). Significant improvement was demonstrated with the Ad-
IFN and ZMAb combinational treatment compared to ZMAb
alone in Ebola virus-infected guinea pigs and in monkeys (96, 97).
Since it is clear that the pathogenicity in Ebola virus infection is
associated with an overactivation of the immune response (77),
we hypothesize that a good candidate for combinational treat-
ment will be one of the immunomodulatory therapeutics that is
already approved by FDA, has been proven to be safe, and is avail-
able in sufficient quantity. It has been shown that dampening the
host’s inflammatory response against influenza virus by use of an
immunomodulatory agent, AAL-R (sphingosine analogue of
FTY720) given in combination with the anti-influenza drug osel-
tamivir provides significantly higher protection (96%) from mor-
tality for mice infected with pathogenic influenza virus over that
the drug oseltamivir alone (50%) (91). It is possible that combi-
national therapy with favipiravir, also an anti-influenza drug
shown to be effective in inhibiting Ebola virus replication in vitro
and in animal models and that is undergoing a trial for its anti-
Ebola virus effect, coadministered with one of the immunomodu-
latory agents discussed above may offer significantly higher treat-
ment efficacy against Ebola. Clearly, further studies need to be
pursued to unravel the impact of combinational treatments for
curing Ebola patients. Of note, rapid and high Ebola virus repli-
cation may give rise to mutations, which may select for resistant
viruses. Due to these resistance issues, combination therapy has a
long history in HIV therapeutics and more recently in hepatitis C
virus therapeutics (98, 99).
TRANSLATIONAL CHALLENGES AND PROSPECTS
All candidate drugs against EVD need to first pass muster in
screening assays or animal studies, preferably in nonhuman pri-
mate experiments, and then in human trials. However, Ebola virus
hemorrhagic fever models, even in nonhuman primates, do not
completely recapitulate the immunological aspects of Ebola virus
infection in humans, and there are considerable differences in
treatment efficacies across different animal models of Ebola virus
infection (100). Rodent species are easier to protect from Ebola
virus infection than are higher species, particularly humans (60).
There is an urgent need to identify therapies that are effective
and safe, and well-designed clinical trials are the fastest and most
reliable way to achieve that goal. Not surprisingly, there has been
substantial debate about the best and most appropriate study ap-
proaches (4, 101). Do the treatments work with any of the avail-
able drugs? And what kind of trial design should be followed to
determine their efficacy against Ebola virus? Is it right to do ran-
domized controlled trials (RCTs), in which some people do not
get the novel intervention? Doctors Without Borders (MSF),
which has led the medical response to the outbreak and in whose
centers in the affected countries the trials are undergoing said
“no” to RCT. Instead, on 13 November 2014, MSF said it would
take part in the trials that would use an alternative design in which
everyone who enrolls receives the untested treatment. All patients
at the MSF centers will get the treatment; their survival rate 14
days later will be compared with survival in earlier patients who
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didn’t receive the treatment. Current trials carried out at MSF
centers may not detect small effects of a drug, but at this time the
goal is to determine whether an intervention is worthless or clearly
works. The trials will be much more acceptable to the local people
if everyone receives high-level care.
A clinical trial of ZMapp started on 27 February 2015, after the
manufacturer had made available sufficient doses of ZMapp to be
employed in the trial. The study is a randomized controlled trial
enrolling adults and children with known Ebola virus infection.
Because the study is not blinded to the caregivers, investigators
will monitor the progression of patients in real time. If ZMapp
does appear to be providing an additional margin of protection, it
will then be added to the control group, and then subsequent
patients may receive one of several other drugs or therapies under
investigation (102).
Because of the stigma that could be attached to a severe emerg-
ing infectious disease in Africa and the frequent resistance of local
people to the testing of unapproved experimental drugs, it seems
that the trial design advocated by MSF is more likely to be adapted
and more realistic.
An introduction of maximum use of supportive therapy
(MUST) will make it easier to study the effects of new treatments
undergoing trial. MUST is likely to reveal side effects of new drugs
that would otherwise be masked by Ebola symptoms, and it could
reduce the rate of complications that might be incorrectly blamed
on a drug. MUST is aimed at keeping more patients alive (103). It
includes the following elements: intravenous (i.v.) drips to replace
massive fluid loss from diarrhea and vomiting, a risk factor for
shock; balancing of electrolytes, such as calcium and potassium, to
prevent kidney and heart failure; nasogastric tubes for feeding;
treatment with antibiotics to combat secondary infections. Ebola
clinics will need more resources to offer MUST.
CONCLUSIONS
Due to the history of multiple outbreaks of Ebola virus infection
and the likelihood of future exposure, the need for developing
efficacious pre- and postexposure treatments is of paramount im-
portance. We have not yet been able to develop any efficacious
drug or vaccine to contain EVD. In this year, three investigational
drugs (favipiravir, convalescent plasma, and ZMapp) are under-
going trials in the affected countries of West Africa. These trials
will provide important information on efficacy and safety of these
drugs and will demonstrate a true predictive power in a clinical
situation. The falling number of Ebola patients may hamper the
ongoing trials. Both ZMapp and TKM-Ebola have worked better
than all other anti-Ebola therapeutics in monkey studies, but they
are relatively difficult to make. Renewed efforts are being made to
scale up their production. Only those therapies available in large
enough quantities to treat the thousands in need of immediate
treatment will be useful in an epidemic situation. There have been
some major advances in the development of a number of thera-
peutics from alternate approaches, including small-molecule-
based compounds. Treatment of Ebola patients with immuno-
modulatory agents already approved by the FDA that can establish
a more balanced and beneficial inflammatory response will bring
clinical benefits to Ebola patients under postexposure conditions.
Instead of waiting for months for forthcoming experimental
drugs, use of repurposed drugs accompanied by simple supportive
therapies might have saved more lives in this recent epidemic. The
importance of further assessing the therapeutic opportunities in
drug combinations needs to be considered, as the use of combi-
national therapy is likely to extend the treatment window and
improve therapeutic efficacy. Some of the investigational drugs
require refrigeration and have to be administered by injection,
which is not ideal with regard to patient compliance in outbreak
scenarios. These concerns underline the importance for adopting
better treatment strategies.
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